( djuvantsare not currently marketed for...)Mymetics' HIV Vaccine Demonstrates First-Ever Production of,Neutralizing IgA Antibodies in Non-Human Primate Model,Health

Dr. Fleury added, "Mymetics and its collaborators are the first group to report neutralizing IgA obtained after vaccination against HIV in non-human primates. In the coming year, Mymetics intends to conduct another study in non-human primates for testing of an improved vaccine version. Pending positive results, we may be able to file to initiate a clinical trial and begin phase I testing some time in late 2008."

Mymetics Vaccine Program Background

Worldwide, over 85 percent of HIV infections are the result of sexual transmission in which mucosal tissues from the genital and anorectal regions have been exposed to HIV-1 present in semen or secretions. According to a recent report from the International AIDS Vaccine Initiative, "Since an effective preventive AIDS vaccine will primarily have to protect an individual from sexual transmission of HIV, researchers think it will probably be important for a vaccine candidate to induce strong mucosal immune responses." Mymetics-affiliated researchers have been able to engineer gp41-derived antigens (proteins and peptides) capable of eliciting antibodies, particularly IgA antibodies, with strong potential for preventing in vitro virus translocation across the mucosal barrier and/or to inhibit cell infection, thus preventing HIV-1 infection.

    Mymetics has combined three important concepts in its vaccine design:


      1- Induction of mucosal and blood antibodies to allow protection in

      different anatomical compartments and block the early event of HIV

      translocation at the genito-reproductive and intestine tracts and

      subsequent infection of target cells underlying the mucosal tissues,

      thereby preventing HIV entry and spreading in the body.


      2- Focusing the immune response against conserved regions on gp41 that

      may induce protective antibodies against a broad range of HIV clades.

      Mymetics is develo
'"/>




Page: 1 2 3 4 
Related medicine technology :

1. Mymetics HIV Vaccine Achieves Research Breakthrough, Eliciting
Protective Antibody Response in Mucosal Tissues of Non-Human
Primate Model
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird
Flu Vaccine
3. DOR BioPharma Announces Issuance of European Patent for Its Oral
Multivalent Botulinum Toxin Vaccine BT-VACC
4. From Clinical Cancer Research: Rethinking Therapeutic Cancer
Vaccine Trials
5. DOR BioPharma Announces Publication Describing Results of Its
Multivalent Botulinum Toxin Vaccine BT-VACC
6. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix
Provides Excellent Protection Against Lesions Caused by Most Common
Cancer-Causing Virus Types
8. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable
Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical
Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
9. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove
Superior at International Conference
10. New Flu Vaccine from PepTcell Could Provide Immunity Against All
Strains of Influenza Virus
11. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure
Reduction During Important Early Morning Period When Most Adverse
Cardiovascular Events Occur